FIELD: biotechnology.
SUBSTANCE: invention relates to the use of a polypeptide in stimulating the growth or recovery of neurons for treating a neurological disorder in a subject, where the polypeptide contains: a light chain of clostridial neurotoxin (L-chain), where the L-chain is catalytically inactive and/or a fragment of a heavy chain of clostridial neurotoxin (H-chain), and wherein the polypeptide does not contain either the HN domain of the clostridial neurotoxin, nor the HC domain of the clostridial neurotoxin.
EFFECT: disclosed are non-toxic polypeptides of Clostridial neurotoxin for use in treating neurological disorders.
18 cl, 10 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
TREATMENT OF SKIN DISEASES | 2021 |
|
RU2840027C1 |
GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
CELLS HIGHLY SENSITIVE TO CLOSTRIDIAL NEUROTOXIN | 2020 |
|
RU2831112C2 |
THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
MODIFIED BOTULINUM NEUROTOXIN FOR TREATING EXTREMITY SPASTICITY | 2021 |
|
RU2841585C1 |
CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
Authors
Dates
2025-04-30—Published
2020-09-30—Filed